Revvity price target raised to $145 from $135 at Citi

Citi raised the firm’s price target on Revvity to $145 from $135 and keeps a Buy rating on the shares post the Q2 report. On the earnings call, management discussed growth drivers including ImmunoDx, Reproductive Health and software, along with ongoing cost initiatives that drove margin outperformance, the analyst tells investors in a research note.